You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTerbutaline
Accession NumberDB00871  (APRD00589)
TypeSmall Molecule
GroupsApproved
DescriptionA selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic. [PubChem]
Structure
Thumb
Synonyms
Terbutalin
Terbutalina
Terbutaline (sulfate de)
Terbutalini sulfas
Terbutalinsulfat
Terbutalinum
External Identifiers
  • KWD 2019
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bricanyl Tab 2.5 mgTablet2.5 mgOralAstrazeneca Canada Inc1978-12-312000-07-20Canada
Bricanyl Tab 5 mgTablet5 mgOralAstrazeneca Canada Inc1975-12-312001-07-23Canada
Bricanyl TurbuhalerPowder, metered0.5 mgRespiratory (inhalation)Astrazeneca Canada Inc1990-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Terbutaline SulfateTablet5 mg/1OralRebel Distributors Corp2005-03-25Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2001-06-26Not applicableUs
Terbutaline SulfateTablet5 mg/1OralAv Kare, Inc.2001-06-262015-12-29Us
Terbutaline SulfateInjection, solution1 mg/mLSubcutaneousGeneral Injectables & Vaccines, Inc2011-11-16Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralLannett Company, Inc.2005-03-25Not applicableUs
Terbutaline SulfateTablet5 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralRebel Distributors Corp2005-03-25Not applicableUs
Terbutaline SulfateTablet5 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2001-06-26Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralAmerican Health Packaging2008-03-122016-01-01Us
Terbutaline SulfateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terbutaline SulfateInjection1 mg/mLSubcutaneousUnited Biomedical Inc., Asia2014-12-15Not applicableUs
Terbutaline SulfateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2001-06-26Not applicableUs
Terbutaline SulfateInjection1 mg/mLSubcutaneousWest ward Pharmaceutical Corp2009-05-20Not applicableUs
Terbutaline SulfateTablet5 mg/1OralAmerican Health Packaging2008-03-122016-01-01Us
Terbutaline SulfateInjection, solution1 mg/mLSubcutaneousAPP Pharmaceuticals, LLC2011-03-10Not applicableUs
Terbutaline SulfateInjection1 mg/mLSubcutaneousAkorn2010-02-01Not applicableUs
Terbutaline SulfateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2005-03-25Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Terbutaline SulfateTablet5 mg/1OralLannett Company, Inc.2005-03-25Not applicableUs
Terbutaline SulfateTablet2.5 mg/1OralAv Kare, Inc.2001-06-262015-12-29Us
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BrethaireNovartis
BrethineNot Available
BricanylAstraZeneca
BricardylJohnson
BricasmaAstraZeneca
BricasolAstraZeneca
DracanylAstraZeneca
TerbasminAstraZeneca
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Terbutaline Sulfate
Thumb
  • InChI Key: MUPQZWGSBCWCAV-UHFFFAOYNA-N
  • Monoisotopic Mass: 323.103872721
  • Average Mass: 323.363
DBSALT000297
Categories
UNIIN8ONU3L3PG
CAS number23031-25-6
WeightAverage: 225.2842
Monoisotopic: 225.136493479
Chemical FormulaC12H19NO3
InChI KeyXWTYSIMOBUGWOL-UHFFFAOYSA-N
InChI
InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
IUPAC Name
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
SMILES
CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
Pharmacology
IndicationFor the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
Structured Indications
PharmacodynamicsTerbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation.
Mechanism of actionThe pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-2 adrenergic receptorProteinyes
agonist
HumanP07550 details
Related Articles
AbsorptionApproximately 30-50% if administered orally and well absorbed subcutaneously.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationAbout 90% of the drug was excreted in the urine at 96 hours after subcutaneous administration, with about 60% of this being unchanged drug. It appears that the sulfate conjugate is a major metabolite of terbutaline and urinary excretion is the primary route of elimination
Half life5.5-5.9 hours
Clearance
  • 311 +/- 112 mL/min
ToxicityTerbutaline Sulfate: Oral LD50(rat) = 8.7 g/kg; Oral LD50(mouse) = 205 mg/kg; Oral LD50(dog) = 1.5 g/kg; IP LD50(rat)= 220 mg/kg ; IP LD50(mouse) = 130 mg/kg; Oral LD50(rabbit) = >8 g/kg; IV LD50(mouse) = 36 mg/kg; IV LD50(dog) = 116 mg/kg; IV LD50(rabbit) = 110 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Terbutaline.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Terbutaline.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Terbutaline.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Terbutaline.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Terbutaline.Illicit, Withdrawn
AmiodaroneTerbutaline may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Terbutaline.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Terbutaline.Approved, Illicit
AnagrelideTerbutaline may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideTerbutaline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTerbutaline may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTerbutaline may increase the QTc-prolonging activities of Asenapine.Approved
AtenololAtenolol may decrease the bronchodilatory activities of Terbutaline.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Terbutaline.Approved
AtosibanThe risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban.Approved
AzithromycinTerbutaline may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineTerbutaline may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideTerbutaline may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Terbutaline.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Terbutaline.Approved, Illicit
Benzylpenicilloyl PolylysineTerbutaline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Terbutaline.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Terbutaline.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Terbutaline.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Terbutaline is combined with Bucindolol.Investigational
BumetanideTerbutaline may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Terbutaline.Approved
CabergolineCabergoline may increase the hypertensive activities of Terbutaline.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Terbutaline.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Terbutaline.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Terbutaline.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
CeritinibTerbutaline may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineTerbutaline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideTerbutaline may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Chlorphentermine.Illicit, Withdrawn
ChlorpromazineTerbutaline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneTerbutaline may increase the hypokalemic activities of Chlorthalidone.Approved
CiprofloxacinTerbutaline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTerbutaline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTerbutaline may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinTerbutaline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terbutaline.Approved, Vet Approved
ClozapineTerbutaline may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibTerbutaline may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Terbutaline.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Terbutaline.Approved
DisopyramideTerbutaline may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.Approved
DofetilideTerbutaline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronTerbutaline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTerbutaline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopamineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Dopamine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Terbutaline.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Terbutaline.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Terbutaline.Approved, Illicit
DronedaroneTerbutaline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolTerbutaline may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Terbutaline.Approved
EliglustatTerbutaline may increase the QTc-prolonging activities of Eliglustat.Approved
EphedrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Terbutaline.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Terbutaline.Approved
ErgonovineErgonovine may increase the hypertensive activities of Terbutaline.Approved
ErgotamineErgotamine may increase the hypertensive activities of Terbutaline.Approved
ErythromycinTerbutaline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTerbutaline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Terbutaline.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Terbutaline.Approved
Etacrynic acidTerbutaline may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Fenoterol.Approved
FlecainideTerbutaline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluoxetineTerbutaline may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTerbutaline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Terbutaline.Approved, Vet Approved
FurosemideTerbutaline may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Gadobenic acidTerbutaline may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinTerbutaline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinTerbutaline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTerbutaline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolTerbutaline may increase the QTc-prolonging activities of Haloperidol.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Terbutaline.Approved
HydrochlorothiazideTerbutaline may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTerbutaline may increase the hypokalemic activities of Hydroflumethiazide.Approved
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Terbutaline is combined with Hydroxyamphetamine hydrobromide.Approved
IbutilideTerbutaline may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneTerbutaline may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline.Approved
IndapamideTerbutaline may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Terbutaline.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Terbutaline.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Terbutaline.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terbutaline.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Isoprenaline.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Terbutaline.Approved
LenvatinibTerbutaline may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideTerbutaline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinTerbutaline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Terbutaline.Approved
LinezolidLinezolid may increase the hypertensive activities of Terbutaline.Approved, Investigational
LopinavirTerbutaline may increase the QTc-prolonging activities of Lopinavir.Approved
LoxapineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Loxapine.Approved
LumefantrineTerbutaline may increase the QTc-prolonging activities of Lumefantrine.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Terbutaline.Withdrawn
MephentermineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Terbutaline.Approved, Investigational
MethadoneTerbutaline may increase the QTc-prolonging activities of Methadone.Approved
MethamphetamineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Terbutaline.Approved
MethyclothiazideTerbutaline may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Terbutaline.Investigational
MetolazoneTerbutaline may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Terbutaline.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Terbutaline.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Terbutaline.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Terbutaline.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Terbutaline.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline.Approved
MoxifloxacinTerbutaline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Terbutaline.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Terbutaline.Approved
NebivololNebivolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline.Withdrawn
NilotinibTerbutaline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Terbutaline.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Terbutaline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline.Withdrawn
OfloxacinTerbutaline may increase the QTc-prolonging activities of Ofloxacin.Approved
OndansetronTerbutaline may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Terbutaline.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Terbutaline.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Terbutaline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline.Approved
PaliperidoneTerbutaline may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTerbutaline may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.Approved
PazopanibTerbutaline may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
PentamidineTerbutaline may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenTerbutaline may increase the QTc-prolonging activities of Perflutren.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terbutaline.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Terbutaline.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Terbutaline.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Terbutaline.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Terbutaline.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Terbutaline.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Terbutaline.Approved, Vet Approved, Withdrawn
PimozideTerbutaline may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Terbutaline.Approved
PiretanideTerbutaline may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Terbutaline.Withdrawn
PolythiazideTerbutaline may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Terbutaline.Approved
PrimaquineTerbutaline may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideTerbutaline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Terbutaline is combined with Procaterol.Approved
PromazineTerbutaline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneTerbutaline may increase the QTc-prolonging activities of Propafenone.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Terbutaline.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Pseudoephedrine.Approved
QuetiapineTerbutaline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneTerbutaline may increase the hypokalemic activities of Quinethazone.Approved
QuinidineTerbutaline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTerbutaline may increase the QTc-prolonging activities of Quinine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Terbutaline.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline.Withdrawn
SaquinavirTerbutaline may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Terbutaline.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Terbutaline.Approved
SotalolSotalol may decrease the bronchodilatory activities of Terbutaline.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Terbutaline.Approved
SulfisoxazoleTerbutaline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SynephrineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Terbutaline.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Terbutaline.Approved
TelavancinTerbutaline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTerbutaline may increase the QTc-prolonging activities of Telithromycin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TetrabenazineTerbutaline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tetryzoline.Approved
ThioridazineTerbutaline may increase the QTc-prolonging activities of Thioridazine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Terbutaline.Approved
TimololTimolol may decrease the bronchodilatory activities of Terbutaline.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Terbutaline.Approved
TorasemideTerbutaline may increase the hypokalemic activities of Torasemide.Approved
ToremifeneTerbutaline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Terbutaline.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.Approved
TrichlormethiazideTerbutaline may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Terbutaline.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Terbutaline.Approved
TyramineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Tyramine.Investigational, Nutraceutical
VandetanibTerbutaline may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibTerbutaline may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Terbutaline.Approved
ZiprasidoneTerbutaline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolTerbutaline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Alison B. Lukacsko, Joseph J. Piala, “Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions.” U.S. Patent US5260333, issued December, 1983.

US5260333
General References
  1. Rhodes MC, Seidler FJ, Abdel-Rahman A, Tate CA, Nyska A, Rincavage HL, Slotkin TA: Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004 Feb;308(2):529-37. Epub 2003 Nov 10. [PubMed:14610225 ]
  2. Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833 ]
  3. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329 ]
External Links
ATC CodesR03CC53R03CC03R03AC03
AHFS Codes
  • 12:12.08.12
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.987
Blood Brain Barrier-0.9355
Caco-2 permeable-0.8404
P-glycoprotein substrateSubstrate0.6335
P-glycoprotein inhibitor INon-inhibitor0.8954
P-glycoprotein inhibitor IINon-inhibitor0.9672
Renal organic cation transporterNon-inhibitor0.9067
CYP450 2C9 substrateNon-substrate0.7678
CYP450 2D6 substrateNon-substrate0.7922
CYP450 3A4 substrateNon-substrate0.6291
CYP450 1A2 substrateNon-inhibitor0.9516
CYP450 2C9 inhibitorNon-inhibitor0.9303
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9115
CYP450 3A4 inhibitorNon-inhibitor0.8766
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9117
Ames testNon AMES toxic0.9119
CarcinogenicityNon-carcinogens0.8484
BiodegradationNot ready biodegradable0.9808
Rat acute toxicity2.1080 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9548
hERG inhibition (predictor II)Non-inhibitor0.9467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Sanofi aventis us llc
  • Aaipharma llc
  • Akorn inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Teva parenteral medicines inc
  • Impax laboratories inc
  • Lannett holdings inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg
TabletOral5 mg
Powder, meteredRespiratory (inhalation)0.5 mg
InjectionSubcutaneous1 mg/mL
Injection, solutionSubcutaneous1 mg/mL
TabletOral2.5 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Terbutaline sulfate powder38.4USD g
Terbutaline Sulfate 1 mg/ml vial12.99USD vial
Terbutaline sulf 1 mg/ml vial4.8USD ml
Brethine 5 mg tablet0.83USD tablet
Terbutaline sulfate 5 mg tablet0.63USD tablet
Brethine 2.5 mg tablet0.57USD tablet
Terbutaline sulfate 2.5 mg tablet0.47USD tablet
Bricanyl Turbuhaler 0.5 mg/dose Metered Inhalation Powder0.08USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point119-122 °CNot Available
water solubility213 mg/mLNot Available
logP0.90TACAKS-NOVAK,K ET AL. (1995)
Caco2 permeability-6.38ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility5.84 mg/mLALOGPS
logP0.55ALOGPS
logP0.44ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)8.86ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity63.04 m3·mol-1ChemAxon
Polarizability24.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as resorcinols. These are compounds containing a resorcinol moiety, which is a benzene ring bearing two hydroxyl groups at positions 1 and 3.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentResorcinols
Alternative Parents
Substituents
  • Resorcinol
  • Aralkylamine
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Schafers RF, Piest U, von Birgelen C, Jakubetz J, Daul AE, Philipp T, Brodde OE: Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. J Cardiovasc Pharmacol. 1999 May;33(5):822-7. [PubMed:10226872 ]
  2. Ramer-Quinn DS, Swanson MA, Lee WT, Sanders VM: Cytokine production by naive and primary effector CD4+ T cells exposed to norepinephrine. Brain Behav Immun. 2000 Dec;14(4):239-55. [PubMed:11120594 ]
  3. Zetterlund A, Hjemdahl P, Larsson K: beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Clin Sci (Lond). 2001 Apr;100(4):451-7. [PubMed:11256987 ]
  4. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T: Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription. J Am Soc Nephrol. 2001 Nov;12(11):2288-99. [PubMed:11675405 ]
  5. Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Riether C, Kavelaars A, Wirth T, Pacheco-Lopez G, Doenlen R, Willemen H, Heijnen CJ, Schedlowski M, Engler H: Stimulation of beta(2)-adrenergic receptors inhibits calcineurin activity in CD4(+) T cells via PKA-AKAP interaction. Brain Behav Immun. 2011 Jan;25(1):59-66. doi: 10.1016/j.bbi.2010.07.248. Epub 2010 Jul 30. [PubMed:20674738 ]
  8. Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE: Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2008 Dec;31(12):2271-2. doi: 10.2337/dc08-0520. Epub 2008 Sep 9. [PubMed:18782903 ]
  9. Hochhaus G, Mollmann H: Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. [PubMed:1358833 ]
  10. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, et al.: Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388-92. [PubMed:2062329 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kovarik Z, Simeon-Rudolf V: Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. J Enzyme Inhib Med Chem. 2004 Apr;19(2):113-7. [PubMed:15449725 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23